Cantor Fitzgerald Reiterates Neutral on Regeneron Pharmaceuticals, Maintains $1015 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald has reiterated a Neutral rating for Regeneron Pharmaceuticals, maintaining a price target of $1015.

September 09, 2024 | 4:06 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cantor Fitzgerald has reiterated a Neutral rating for Regeneron Pharmaceuticals, maintaining a price target of $1015.
The reiteration of a Neutral rating and maintenance of the price target suggests that Cantor Fitzgerald does not expect significant short-term changes in Regeneron's stock price. This indicates a stable outlook, which is neither bullish nor bearish.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100